Cargando…
Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps
BACKGROUND: Dupilumab is the first monoclonal antibody therapy to be approved in Canada for the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). The goal of the study was to assess its effectiveness and efficacy in a real-world setting. This study aims to assess how clinical outcomes...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036753/ https://www.ncbi.nlm.nih.gov/pubmed/35468866 http://dx.doi.org/10.1186/s40463-022-00570-0 |